ResearcherNational Cancer InstituteNo recent work listed

Jane B Trepel

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7681-6554; OpenAlex author ID A5040289016; NIH RePORTER profile ID 6572214. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 1
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: none · 2023: 1 grant

Papers 1

Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-19-2586 ↗

Grants 1

Signal Transduction Events and the Regulation of Cell Growth ZICSC006743 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Raffit Hassan · 1 shared paper, 2020 · strength 0.10
- Paper Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreat… DOI 10.1158/1078-0432.ccr-19-2586 ↗
Ira Pastan · 1 shared paper, 2020 · strength 0.10
- Paper Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreat… DOI 10.1158/1078-0432.ccr-19-2586 ↗
Christine Alewine · 1 shared paper, 2020 · strength 0.10
- Paper Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreat… DOI 10.1158/1078-0432.ccr-19-2586 ↗
William Douglas Figg · 1 shared paper, 2020 · strength 0.10
- Paper Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreat… DOI 10.1158/1078-0432.ccr-19-2586 ↗
Zishuo I. Hu · 1 shared paper, 2020 · strength 0.10
- Paper Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreat… DOI 10.1158/1078-0432.ccr-19-2586 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.